Skip to content

Contribution of PRF in CDH in Children With Prothetic Patch Closure

Contribution of PRF (Platelet Rich Fibrin) in the Biological Functionalization of Prothetic Patch Closure : in Vitro Study

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03861182
Acronym
HECODIAP
Enrollment
30
Registered
2019-03-04
Start date
2019-09-12
Completion date
2019-12-10
Last updated
2021-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Diaphragmatic Hernias

Brief summary

Improved management of giant congenital diaphragmatic hernias (CDH) in neonates : decreased risk of morbidity and mortality due to prosthesis release. CDH is a rare disease with a still very dark prognosis, with a high rate of morbidity and mortality in giants forms linked to the release of insufficiently biologically integrated prosthesis. The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.

Interventions

BIOLOGICALBiological functionalization of the prosthetic materials by PRF

The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to No maximum
Healthy volunteers
Yes

Inclusion criteria

Adult Healthy Volunteers : \- Over 18 years of age Neonates: * Aged between 1h of life and 28 days of life * Born beyond 33 Week of Amenorrhea + 1day and 2kg of birth weight * Hospitalized in the medical-surgical centre of Pediatrics of the hospital of Strasbourg * For whom a blood sample was prescribed as part of their routine care

Exclusion criteria

Adult Healthy Volunteers : * Systemic inflammatory disease * Transient inflammatory state * Any drug that modifies the coagulation cascade during the 48h preceding the sampling Neonates: * Risk of anemia \< 7g/DL * Current anticoagulant treatment

Design outcomes

Primary

MeasureTime frameDescription
Comparison of cell colonization between neonate biomaterials and the same biomaterials functionalized by Platelet Rich Fibrin of healthy adult volunteers.7 daysAnalysis of cell colonization after cell culture.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026